Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer

NCT07446686 is registered in ClinicalTrials.gov with Guizhou Provincial People's Hospital as lead sponsor.

NCT NCT07446686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07446686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer
Lead sponsor
Guizhou Provincial People's Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer